Gregory Morris is a partner at O’Melveny. Armed with more than 20 years of legal experience and a Ph.D. in Organic Chemistry from Northwestern University, Gregory’s practice focuses on pharmaceutical, biotechnology, and medical device patent litigation. He represents the industry's most sophisticated companies on the brand-side in Hatch-Waxman litigation and regularly litigates inter partes review (IPR) proceedings before the US Patent & Trademark Office (USPTO).

Lauded as “one of the very best IP strategists,” clients note his “analytical ability — when he's faced with an issue he looks into it analytically from the outset.” Gregory is considered to be “a great communicator who really digs into the science and explains things in layman's terms”(Chambers USA). Gregory co-led a team of attorneys, for example, in the first-ever successful defense of an Orange Book-listed patent in an IPR review.

Among other accolades, Gregory is recognized in Chambers USA. IAM Patent 1000 recognized Gregory among the “World’s Leading Patent Practitioners” each year since 2020. He was recognized in the Crain’s Chicago Business 2019 list of “Notable Gen X Leaders in Law.” He has been named a Patent Star by Managing IP each year since 2016. And he has been recognized as a Life Sciences Star by LMG Life Sciences each year since 2017. Gregory has also been quoted extensively in the media and writes and lectures widely on Hatch-Waxman litigation, biologics, and the PTAB.